Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (161-170 of 194) with videos related to

Pageof 20
Sort By:
Cancer Chemotherapy and Pharmacology|June 15, 2007
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I studyJ Bonneterre, M Campone, P Koralewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Bonneterre, B Thürlimann, J F Robertson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study GroupB Thürlimann, R Paridaens, D Serin, et al.
British Journal of Cancer|September 24, 2004
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancerJ Bonneterre, V Dieras, M Tubiana-Hulin, et al.
The Journal of Infusional Chemotherapy|January 1, 1995
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancerM Hebbar, J Bonneterre, C Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Fotemustine plus dacarbazine for malignant melanomaM F Avril, J Bonneterre, D Cupissol, et al.
Cancer|November 1, 1990
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesC Jacquillat, D Khayat, P Banzet, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanomaC Jacquillat, D Khayat, P Banzet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.
Annales De Pathologie|April 1, 1997
[Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity]M O Vilain, A Delobelle-Deroide, F Bloget, et al.
Pageof 20

Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|June 15, 2007
Vinorelbine/docetaxel combination treatment of metastatic breast cancer: a phase I studyJ Bonneterre, M Campone, P Koralewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2000
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability studyJ Bonneterre, B Thürlimann, J F Robertson, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study GroupB Thürlimann, R Paridaens, D Serin, et al.
British Journal of Cancer|September 24, 2004
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancerJ Bonneterre, V Dieras, M Tubiana-Hulin, et al.
The Journal of Infusional Chemotherapy|January 1, 1995
Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancerM Hebbar, J Bonneterre, C Fournier, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Fotemustine plus dacarbazine for malignant melanomaM F Avril, J Bonneterre, D Cupissol, et al.
Cancer|November 1, 1990
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesC Jacquillat, D Khayat, P Banzet, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanomaC Jacquillat, D Khayat, P Banzet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.
Annales De Pathologie|April 1, 1997
[Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity]M O Vilain, A Delobelle-Deroide, F Bloget, et al.
Pageof 20